PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20170802 164902
20180131 135940
DJI 0031
IMG-20170807-WA0020
20170804 152706
20180815 152016
  • Spikevax and Moderna COVID-19 Vaccine
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-07-01 By FDA
  • Pulmonary-Allergy Drugs Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Patient Labeling Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Human medicines European public assessment report (EPAR): Uptravi, selexipag, Hypertension, Pulmonary, Date of authorisation: 12/05/2016, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung;Breast Neoplasms;Ovarian Neoplasms;Colorectal Neoplasms;Carcinoma, Renal Cell, Date of authorisation: 12/01/2005, Revision: 60, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Anxiety Disorders;Neuralgia;Epilepsy, Date of authorisation: 19/06/2015, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Executive Careers at CDER
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-07-01 By FDA
  • Human medicines European public assessment report (EPAR): Cuprymina, copper (64Cu) chloride, Radionuclide Imaging, Date of authorisation: 23/08/2012, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Epilepsy, Date of authorisation: 03/10/2011, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Pregabalin Sandoz GmbH, pregabalin, Anxiety Disorders;Epilepsy, Date of authorisation: 19/06/2015, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Zostavax, shingles (herpes zoster) vaccine (live), Herpes Zoster;Immunization, Date of authorisation: 19/05/2006, Revision: 33, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), COVID-19 virus infection, Date of authorisation: 24/06/2022, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Ristfor, sitagliptin,metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
  • Human medicines European public assessment report (EPAR): Rydapt, midostaurin, Leukemia, Myeloid, Acute;Mastocytosis, Date of authorisation: 18/09/2017, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-07-01
Older posts
Theme: Scaffold by Danny Cooper.